MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

548.05 +7.79 (+1.44%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,074,992
Open 545.10
Bid (Size) 547.05 (40)
Ask (Size) 548.00 (40)
Prev. Close 540.26
Today's Range 540.70 - 555.32
52wk Range 374.17 - 555.32
Shares Outstanding 259,428,394
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Vertex Pharmaceuticals: A Biotech Cash Cow With Pipeline Upside? ↗
Vertex dominates cystic fibrosis and has a debt-free balance sheet, but can its pipeline restore faster growth? See why our analysts gave the stock a strong 7.3 out of 10. 
Via The Motley Fool
News headline image
CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money? ↗
This year, the biotech stock has underperformed both the Nasdaq Biotechnology Index and the S&P 500. 
Via The Motley Fool
Topics ETFs Stocks

Performance

YTD
+21.2%
+21.2%
1 Month
+16.0%
+16.0%
3 Month
+26.1%
+26.1%
6 Month
+14.9%
+14.9%
1 Year
+37.9%
+37.9%

More News

Read More
News headline image
Uber, ServiceNow And A Health Care Stock On CNBC’s ‘Final Trades’ ↗
Via Benzinga
News headline image
Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead ↗
Via The Motley Fool
Vertex Pharmaceuticals (NASDAQ:VRTX): Strong Growth and Textbooks Technical Setup for Breakout ↗
Via Chartmill
Vertex Pharmaceuticals (NASDAQ:VRTX): An Affordable Growth Stock Balancing Strong Fundamentals With Reasonable Valuation ↗
Via Chartmill
News headline image
3 Cash-Producing Stocks on Our Watchlist
Via StockStory
News headline image
Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More ↗
Via The Motley Fool
News headline image
$100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth This Much Today ↗
Via Benzinga
News headline image
Vertex (VRTX) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
Discover which S&P500 stocks are making waves on Monday. ↗
Via Chartmill
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
Get insights into the top movers in the S&P500 index of Monday's pre-market session. ↗
Via Chartmill
News headline image
5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q2 Earnings Call
Via StockStory
Topics Earnings
News headline image
Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire? ↗
Via The Motley Fool
News headline image
Why Vertex Pharmaceuticals Stock Ticked Higher on Tuesday ↗
Via The Motley Fool
News headline image
Vertex Pharmaceuticals Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q2 CY2026 Sales Expectations, Full-Year Outlook Slightly Exceeds Expectations
Via StockStory
News headline image
Vertex Reports Second Quarter 2026 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Pharmaceuticals (VRTX) Q2 Earnings Report Preview: What To Look For
Via StockStory
Topics Artificial Intelligence
News headline image
Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target ↗
Via The Motley Fool
News headline image
Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy? ↗
Via The Motley Fool
News headline image
AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions
From AbCellera Biologics Inc.
Via Business Wire
News headline image
3 Healthcare Stocks with Competitive Advantages
Via StockStory
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TriCo Bancshares (Nasdaq – TCBK), Twin Vee PowerCats Co. (Nasdaq -VEEE), Crinetics Pharmaceuticals, Inc. (Nasdaq – CRNX), Element Solutions Inc. (NYSE – ESI)
From Brodsky & Smith LLC
Via GlobeNewswire

Frequently Asked Questions

Is Vertex Pharmaceuticals publicly traded?
Yes, Vertex Pharmaceuticals is publicly traded.
What exchange does Vertex Pharmaceuticals trade on?
Vertex Pharmaceuticals trades on the Nasdaq Stock Market
What is the ticker symbol for Vertex Pharmaceuticals?
The ticker symbol for Vertex Pharmaceuticals is VRTX on the Nasdaq Stock Market
What is the current price of Vertex Pharmaceuticals?
The current price of Vertex Pharmaceuticals is 548.05
When was Vertex Pharmaceuticals last traded?
The last trade of Vertex Pharmaceuticals was at 08/21/26 04:00 PM ET
What is the market capitalization of Vertex Pharmaceuticals?
The market capitalization of Vertex Pharmaceuticals is 142.18B
How many shares of Vertex Pharmaceuticals are outstanding?
Vertex Pharmaceuticals has 142B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story